IONIS PHARMACEUTICALS INC - 8-K Filing
Ionis Pharmaceuticals partner Novartis announced the Phase 3 Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $IONS